Literature DB >> 28340008

Pre-treatment interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients.

Yasushi Kondo1, Yuko Kaneko1, Hiroaki Sugiura2, Shunsuke Matsumoto2, Naoshi Nishina1, Masataka Kuwana1,3, Masahiro Jinzaki2, Tsutomu Takeuchi1.   

Abstract

Objective: To examine the relationship between MRI structural damage and repair and plasma inflammatory cytokines in patients with RA.
Methods: A total of 88 newly diagnosed, untreated RA patients were enrolled. Contrast MRI of the dominant hand and X-rays of the hands and feet were performed at baseline and 1 year later. MR images were evaluated using RA MRI scoring, and X-ray.
Results: Progression of bone erosion and repair were observed more frequently in MRI than in X-rays (erosion, 52% vs 26%, P < 0.001; repair, 26% vs 15%, P = 0.003, respectively). Baseline IL-6 levels and seropositivity were independent relevant factors for MRI erosion progression, with IL-6 having stronger effect than seropositivity. A receiver operating characteristic curve identified the baseline IL-6 level of 7.6 pg/ml for predicting erosion progression during 1 year, with an area under the curve of 0.82; higher IL-6 levels resulted in more erosion progression. Baseline low IL-6 was also an independent predictor for MRI erosion repair.
Conclusion: In newly diagnosed, untreated RA patients, baseline plasma IL-6 levels are responsible for 1-year MRI bone erosion progression and repair.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  IL-6; bone erosion; cytokines; magnetic resonance imaging; repair; rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28340008     DOI: 10.1093/rheumatology/kex046

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

Review 1.  IL-27: a double agent in the IL-6 family.

Authors:  G W Jones; D G Hill; A Cardus; S A Jones
Journal:  Clin Exp Immunol       Date:  2018-03-09       Impact factor: 4.330

2.  Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.

Authors:  Mark C Genovese; Roy Fleischmann; Alan Kivitz; Eun-Bong Lee; Hubert van Hoogstraten; Toshio Kimura; Gregory St John; Erin K Mangan; Gerd R Burmester
Journal:  Arthritis Res Ther       Date:  2020-06-10       Impact factor: 5.156

3.  Multimodal [18 F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice.

Authors:  Silvia Hayer; Markus Zeilinger; Volker Weiss; Monika Dumanic; Markus Seibt; Birgit Niederreiter; Tetyana Shvets; Florian Pichler; Wolfgang Wadsak; Bruno K Podesser; Thomas H Helbich; Marcus Hacker; Josef S Smolen; Kurt Redlich; Markus Mitterhauser
Journal:  J Bone Miner Res       Date:  2019-07-30       Impact factor: 6.741

4.  [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].

Authors:  Song Luo; Lijuan Yang; Chun Wang; Chuanmiao Liu; Dianming Li
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.